FINNENCE ▪ THE WIRE FILE
THE WIRE · № 55945
SEC Filing■ Unclear/unknown
TSLA filed 8-K on 2026-09-29
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-29 00:00 UTC
LAST UPDATE2026-09-29 00:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
An 8-K with material agreement, termination, and indebtedness items signals corporate-level changes that could affect TSLA's capital structure or obligations.
Material agreement and debt items warrant closer TSLA review
CATALYST TO WATCH
Details of the agreement or debt terms
MAIN RISK
Unclear terms could mask unfavorable obligations
FULL DISPATCH
TSLA (CIK 0001318605) filed a 8-K on 2026-09-29. 8-K items: item 1.01 (material agreement) item 1.02 (agreement terminated) item 2.03 (indebtedness) item 9.01.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTTesla · TSLA
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Compare GNR-139 and Eylea® in Patients With nAMD — AO GENERIUM2026-09-28 12:00 UTC
New Phase 3 trial: A Study to Compare GNR-139 and Eylea® in Patients With nAMD — AO GENERIUM2026-09-28 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease — Hoffmann-La Roche2026-09-28 12:00 UTC
New Phase 3 trial: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease — Hoffmann-La Roche2026-09-28 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day — Idorsia Pharmaceuticals Ltd.2026-09-28 12:00 UTC
New Phase 3 trial: A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day — Idorsia Pharmaceuticals Ltd.2026-09-28 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: The Safety and Efficacy of HR19034 in Children With Myopia — Chengdu Suncadia Medicine Co., Ltd.2026-09-28 12:00 UTC
New Phase 3 trial: The Safety and Efficacy of HR19034 in Children With Myopia — Chengdu Suncadia Medicine Co., Ltd.2026-09-28 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin — Adneuris Therapeutics, Inc.2026-09-28 12:00 UTC
New Phase 3 trial: An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin — Adneuris Therapeutics, Inc.2026-09-28 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years — Janssen Research & Development, LLC2026-09-28 12:00 UTC
Phase 3 results posted: A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years — Janssen Research & Development, LLC2026-09-28 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.